Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.

Blood cancer journal - 11 Sept 2023

Liu Enze, Sudha Parvathi, Becker Nathan, Jaouadi Oumaima, Suvannasankha Attaya, Lee Kelvin, Abonour Rafat, Abu Zaid Mohammad, Walker Brian A

Abstract excerpt

Biallelic TP53 inactivation is the most important high-risk factor associated with poor survival in multiple myeloma. Classical biallelic TP53 inactivation has been defined as simultaneous mutation and copy number loss in most studies; however, numerous studies have demonstrated that other factors could lead to the inactivation of TP53. Here, we hypothesized that novel biallelic TP53 inactivated samples existed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to TP53 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Mutation

Share to RNA Splicing Factors

Share to Transcription Factors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 37696786
DOI: 10.1038/s41408-023-00919-2
PMCID: PMC10495448

Genes

TP53
MED18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.PMID 37696786Read ↗

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.Semantic proximity Read ↗

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaSemantic proximity Read ↗

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.Semantic proximity Read ↗

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisSemantic proximity Read ↗

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.Semantic proximity Read ↗

Subclonal TP53 copy number is associated with prognosis in multiple myelomaSemantic proximity Read ↗

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.Semantic proximity Read ↗

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read ↗

Genomic characterization of functional high-risk multiple myeloma patients.Semantic proximity Read ↗

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.